All In Biotech

Drug Trial Radar · NCT06344104

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

326

Actual

Start

Apr 8, 2024

Primary completion

Nov 24, 2025

Study completion Apr 3, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the efficacy and safety of baxdrostat in participants with uHTN or rHTN. The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between participants receiving 2 mg baxdrostat or 1 mg baxdrostat tablets and participants receiving placebo tablets.

Conditions

  • Uncontrolled Hypertension
  • Resistant Hypertension

Interventions

  • BaxdrostatDrug

    Baxdrostat tablet administered orally, once daily (QD). Unit dose strength: * 1 mg per tablet for 1mg baxdrostat Arm * 2 mg per tablet for 2mg baxdrostat Arm

  • PlaceboDrug

    Placebo tablet administered orally, once daily (QD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in seated SBP at Week 12Time frame: At Week 12

Locations

93 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Bahía Blanca, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    San Miguel de Tucumán, Argentina

  • Research Site

    San Nicolás de los Arroyos, Argentina

  • Research Site

    Coffs Harbour, Australia

  • Research Site

    Gosford, Australia

  • Research Site

    Hoppers Crossing, Australia

  • Research Site

    Ipswich, Australia

  • Research Site

    Baotou, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Bengbu, China

  • Research Site

    Changde, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Changzhou, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Chongqing, China

  • Research Site

    Chongqing, China

  • Research Site

    Deyang, China

  • Research Site

    Guangzhou, China

  • Research Site

    Ha’erbin, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Heze, China

  • Research Site

    Jiujiang, China

  • Research Site

    Luoyang, China

  • Research Site

    Meihekou, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanchong, China

  • Research Site

    Nanjing, China

  • Research Site

    Panjin, China

  • Research Site

    Sanya, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Shenyang, China

  • Research Site

    Taiyuan, China

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.